34844-80-9

Usage

Uses

Used in Pharmaceutical Research and Development:
4,5-Dihydro-1,4-benzoxazepin-3(2H)-one is used as a potential pharmaceutical agent for its demonstrated biological activities, including anti-inflammatory, antibacterial, and antifungal properties. Its unique structure and medicinal potential make it a valuable compound for ongoing scientific investigation and development.
Used in Neurodegenerative Disease Treatment:
In the field of neurology, 4,5-dihydro-1,4-benzoxazepin-3(2H)-one is used as a candidate for the treatment of neurodegenerative diseases. Its potential in this area is attributed to its ability to target specific biological pathways implicated in the progression of such diseases.
Used in Antipsychotic Drug Development:
4,5-Dihydro-1,4-benzoxazepin-3(2H)-one is also being studied for its potential as an antipsychotic agent. Its use in this context is driven by its capacity to modulate neurotransmitter systems and potentially alleviate symptoms associated with psychotic disorders.
Used in Antibacterial Applications:
In the field of microbiology, 4,5-dihydro-1,4-benzoxazepin-3(2H)-one is used as an antibacterial agent, leveraging its ability to combat bacterial infections and contribute to the development of new antimicrobial therapies.
Used in Antifungal Applications:
Similarly, in the realm of antifungal treatment, 4,5-dihydro-1,4-benzoxazepin-3(2H)-one is utilized for its antifungal properties, offering a potential solution to combat fungal infections and contributing to the advancement of antifungal drug development.

InChI:InChI=1/C9H9NO2/c11-9-6-12-8-4-2-1-3-7(8)5-10-9/h1-4H,5-6H2,(H,10,11)

Upstream product

• 34844-79-6 methyl 2-(2-cyanophenoxy)ethanoate 
• 92970-91-7 benzo[f][1,4]thiazepine-3,5-dione 
• 611-20-1 salicylonitrile 
• 618886-56-9 2-chloro-N-(2-hydroxybenzyll)acetamide 

Downstream Products

• 17775-01-8 2.3.4.5-Tetrahydro-benzo[f][1,4]oxazepine 

Relevant academic research and scientific papers

Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors

A novel benzoazepinequnoline (BAQ) series was discovered as RSV fusion inhibitors. BAQ series originated from compound 2, a hit from similarity-based virtual screening. In SAR exploration, benzoazepine allowed modifications in the head moiety. Benzylic sulfonyl on benzoazepine and 6-Me on quinoline were crucial for good anti-RSV activity. Although the basic amine in the head portion was crucial for anti-RSV activity, the attenuated basicity was required to reduce Vss. Introducing oxetane to the head portion led to discovery of compound 1, which demonstrated single-digit nM anti-RSV activity against different RSV strains, reasonable oral exposure in plasma, and 78-fold higher exposure in lung. Compound 1 also displayed 1 log viral reduction in a female BALB/c mice RSV model by b.i.d. oral dosing at 12.5 mg/kg. A single resistant mutant at L138F in fusion protein proved compound 1 to be a RSV fusion inhibitor.

Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan

A new series of 1,4-benzoxazepine derivatives was designed, synthesized, and evaluated for binding to 5-HT1A receptor and cerebral anti-ischemic effect. A lot of compounds exhibited nanomolar affinity for 5-HT1A receptor with good selectivity over both dopamine D 2 and α1-adrenergic receptors. Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]- 1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model.